TLR3

TLR3

TLR3 Molekülinformation

Molecule Name
Toll like receptor 3
Molekülalias
TLR3,CD283,IIAE2
Drug Development Progress
Anzahl der klinischen Arzneimittel7
Anzahl der inverkehr gebrachten Arzneimittel1
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
CD283,TLR3,Toll Like Receptor 3,Toll-Like Receptor 3,CD283 Antigen,IIAE2
Molekülhintergrund
Toll-like receptor 3 (TLR3) is also known as CD283, which belongs to the Toll-like receptor family which plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 / CD283 contains 22 LRR (leucine-rich) repeats, 1 LRRCT domain, 1 LRRNT domain and 1 TIR domain. TLR3 is expressed at high level in placenta and pancreas and also detected in CD11c+ immature dendritic cells. CD283 / TLR3 is only expressed in dendritic cells. TLR3 is the TLR that is expressed most strongly in the brain, especially in astrocytes, glia, and neurons. CD283 / TLR-3 is the key component of innate and adaptive immunity. TLR3 / CD283 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. TLR3 acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Defects in TL-R3 are associated with herpes simplex encephalitis type 2 (HSE2).

TLR3 Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
TR-987Z-101; GLYC-101; MG-3601; TR-987Phase 3 ClinicalKazia Therapeutics
Varicose Ulcer; Varicose Veins; Wounds and Injuries
Details
Monovalent norovirus Vaccine (Vaxart)VXA-G1-1-NN; VXA-G1.1-NNPhase 2 ClinicalVaxart Inc
Norovirus Infections
Details
Poly ICLC (Oncovir)Phase 2 ClinicalNational Institutes Of Health, Oncovir Inc
Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Esophageal Neoplasms; Glioma; HIV Infections; Low-grade Glioma; Lymphoma, B-Cell; Lymphoma, T-Cell; Melanoma; Mesothelioma; Metastatic breast cancer; Neoplasms; Osteosarcoma; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Stomach Neoplasms; Urinary Bladder Neoplasms
Details
BO-112BO-112Phase 2 ClinicalHighlight Therapeutics SL
Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Dermatofibrosarcoma; Esophageal Neoplasms; Fibrosarcoma; Histiocytoma, Malignant Fibrous; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasms; Neurofibrosarcoma; Rhabdomyosarcoma; Sarcoma; Sarcoma, Synovial; Stomach Neoplasms
Details
Monovalent norovirus Vaccine (Vaxart)/VXA-G2-4-NSVXA-NVV-201Phase 2 ClinicalVaxart Inc
Norovirus Infections
Details
CNTO-5CNTO-5Phase 1 ClinicalMorphosys Ag
Inflammation
Details
PGV-001PGV-001Phase 1 ClinicalGenentech Inc, Icahn School Of Medicine At Mount Sinai
Neoplasms; Urologic Neoplasms
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
RintatolimodAMP-516; AMP-518ApprovedHemispherx Biopharma IncRintamod, AmpligenArgentinaFatigue Syndrome, ChronicHemispherx Biopharma Inc2017-01-01
Breast Neoplasms; Breast Neoplasms, Male; Colorectal Neoplasms; Fatigue Syndrome, Chronic; HIV Infections; HIV Seropositivity; Influenza, Human; Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Post-Acute COVID-19 Syndrome
Details